Retatrutide Research Peptide 15 mg
For research use only. Not for human consumption.15 mg
$189.00
Triple incretin receptor agonist. GLP-1R / GIPR / GCGR. CAS 2381089-83-2.
An investigational triple-receptor agonist (GLP-1, GIP and glucagon pathways) in Phase 3 metabolic research, including obesity and type 2 diabetes. Not an approved drug.
Ordering is closed. This product becomes purchasable when a lot for it has been released and its certificate published.
Single-vial price. Volume pricing begins at 2 vials.
One unit is one vial. The per-vial price changes at 2, 6, 25, 50 and 100 vials; between those points it does not change.
An inquiry is a question about availability, never an order.
Below 100 vials the price is published, not quoted. The band your quantity falls into is applied automatically at checkout.
Research Use Only Purchasers must be 21+
Release requires
- Certificate of analysisNone on fileSigned by a named, independent, contactable laboratory.Why independence matters
- ChromatogramNone on fileFull trace as issued, not a redrawn summary.How a trace is read
- Identity confirmationNone on fileMethod and result as reported, never as summarised.Identity is not purity
- Lot recordNone on fileOne permanent address per lot, kept whatever the outcome.What a lot record holds
No purity figure, identity result, laboratory name or test date appears anywhere on this page, because none has been recorded for this product.
Description
Synthetic 39-residue peptide carrying a C20 fatty diacid at Lys17. Also identified as LY3437943. CAS 2381089-83-2. Molecular weight approximately 4,731 Da. Supplied as lyophilized powder, 15 mg per vial.
Learn the science Mechanism and pathway for Retatrutide
One molecule, three receptors
Retatrutide is a single synthetic peptide reported to act at three separate receptors. This is what published research describes at each one.
Retatrutide
What you're seeing
A laboratory-made peptide designed to act on three different receptors at once, rather than one. It is investigational: it has not been approved for any use.
Scientific detail
Described in the literature as a triple receptor agonist peptide, developed under the code LY3437943. An agonist is a molecule that binds a receptor and activates it. Acting at three receptors with one molecule is the property being studied here; single-receptor and dual-receptor agonists are separate, earlier classes of compound.
Where a receptor sits
What you're seeing
A receptor is not free-floating. It spans the wall of a cell, so that something arriving on the outside can start a signal on the inside. All three receptors here are built that way.
Scientific detail
GLP-1R, GIPR and the glucagon receptor are G-protein-coupled receptors with a seven-transmembrane architecture: seven segments crossing the membrane, an outward-facing side that binds, and an inward-facing side that signals. That shared architecture is why one molecule can be studied at all three. The drawing is a schematic of that arrangement, not a resolved structure.
GLP-1R
What you're seeing
The receptor for GLP-1, a gut hormone involved in blood-sugar regulation and appetite signaling. It is the best-established of the three, and the mechanism behind an existing, widely studied drug class.
Scientific detail
Glucagon-like peptide-1 receptor. In the published discovery pharmacology, in-vitro activity at this receptor was reported as balanced with activity at the glucagon receptor. Reduced calorie intake in preclinical models was attributed to GLP-1 and GIP receptor activity.
GIPR
What you're seeing
The receptor for GIP, another gut hormone released after eating. It is being studied for effects that may add to, or differ from, GLP-1 receptor activity.
Scientific detail
Glucose-dependent insulinotropic polypeptide receptor. The discovery pharmacology reported greater in-vitro activity at this receptor than at the other two. Whether combined GIP and GLP-1 receptor activity is meaningfully different from GLP-1 receptor activity alone is an active research question, not a settled one.
GCGR
What you're seeing
The receptor for glucagon, a hormone involved in how the body uses stored energy. It is the component that distinguishes this compound from dual-receptor agonists.
Scientific detail
In the cited preclinical work, glucagon-receptor activity was associated with increased energy expenditure, reported alongside the reduced calorie intake attributed to the other two receptors. This describes what that study measured in its models. It is not a predicted result in a person.
Triple-receptor agonism
What you're seeing
The research question is whether activating all three receptors with one molecule behaves differently from activating one or two. That question is still being answered in clinical trials.
Scientific detail
A phase 1b trial in adults with type 2 diabetes and a phase 2 trial in adults with obesity have been published, and a phase 3 program is registered on ClinicalTrials.gov. A published trial result is evidence; it is not the same thing as an approved use, which follows full regulatory review.
Simplified pathway, drawn for educational purposes. It shows what published research describes about the molecule. It does not describe a result in a person, and it is not a claim about NuePharma material.
Lot recordNo lot published yet
No lot published for this product yet. Nothing ships without a certificate.
Keep going
Go deeper into the science.
Discover the compounds, pathways and research systems connected to what you're already exploring.
Adjacent research pathways
-
Tesamorelin
For research use only. Not for human consumption.Explore a different side of metabolic and endocrine research through the GHRH and GH/IGF-1 axis.
-
Ipamorelin
For research use only. Not for human consumption.Explore ghrelin-receptor signaling and growth-hormone release in a separate but related research context.
Research systems Metabolic pathways Endocrine signaling
These are separate research materials with separate research records. Nothing here suggests combining them, and no connection above is a claim about using more than one.
Why this format
We intentionally selected this vial configuration as a balanced format for laboratory research—substantial enough for practical experimental planning without unnecessarily increasing the quantity contained in an individual vial. Each vial remains individually traceable to its corresponding lot record and supporting documentation.
Stability & storage
Refer to the product’s applicable documentation and labeled storage conditions. NuePharma does not assign generalized post-reconstitution or expiration periods unless supported by product-specific documentation.